Price · as of 2024-12-31
$10.79
Market cap 1.39B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $193.10 | +1,689.62% |
| Intrinsic Value(DCF) | $5.10 | -52.73% |
| Graham-Dodd Method(GD) | $7.00 | -35.13% |
| Graham Formula(GF) | $30.90 | +186.38% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $9.75 | ||||
| 2019 | $10.59 | $73.52 | $229,993.32 | $0.00 | $0.00 |
| 2020 | $10.95 | $69.19 | $2,846.18 | $0.00 | $0.00 |
| 2021 | $7.08 | $28.85 | $109.32 | $0.00 | $0.00 |
| 2022 | $7.67 | $127.79 | $108,940.06 | $7.00 | $253.50 |
| 2023 | $12.27 | $43.97 | $4.80 | $0.00 | $81.30 |
| 2024 | $4.66 | $165.03 | $24,843.65 | $7.00 | $30.90 |
AI valuation
Our deep-learning model estimates Immatics N.V.'s (IMTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $193.10
- Current price
- $10.79
- AI upside
- +1,689.62%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.10
-52.73% upside
Graham-Dodd
$7.00
-35.13% upside
Graham Formula
$30.90
+186.38% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IMTX | Immatics N.V. | $10.79 | 1.39B | +1,429% | -53% | -35% | +186% | 28.44 | 0.75 | 2.78 | -4.51 | — | 0.76 | 100.00% | -24.78% | 9.77% | 3.80% | 27.69% | 2.52% | 0.03 | -43.58 | 9.26 | 8.99 | -6.40 | -11167.00% | 18860.00% | 127096.00% | -40.32% | -2.32 | 175.55% | 0.00% | 0.00% | 4.04% | 4.03 | 0.89 | -1.00 | 1.96 |
| ATAI | Atai Beckley N.V | $3.63 | 684.71M | +564% | -83% | — | — | -1.61 | 2.08 | 785.20 | -1.41 | -0.59 | 2.15 | 100.00% | -33341.23% | -48463.96% | -83.53% | -126.85% | -66.27% | 0.21 | -32.87 | 3.21 | 2.55 | -0.05 | 27200.00% | -191.00% | -257.00% | -34.13% | -3.30 | -102.19% | 0.00% | 0.00% | 0.00% | -1.99 | -2.47 | 663.04 | -4.47 |
| CVAC | CureVac N.V. | $4.66 | 1.05B | +3,460% | -35% | +67% | +15,600% | 3.05 | 0.84 | 1.09 | 0.65 | — | 0.87 | 80.23% | 33.20% | 30.30% | 31.46% | 74.77% | 23.99% | 0.06 | — | 7.28 | 7.16 | -2.11 | -16102.00% | 89554.00% | -12582.00% | 14.31% | 1.41 | 41.31% | 0.00% | 0.00% | 14.10% | 0.77 | 1.64 | 0.25 | 2.92 |
| ELVN | Enliven Therapeutics, Inc… | $29.69 | 1.76B | — | — | — | — | -11.10 | 3.19 | — | -6.48 | — | 3.19 | 0.00% | — | — | -32.04% | 1991.13% | -29.79% | 0.00 | — | 19.99 | 19.69 | 1.19 | -597.00% | — | 1924.00% | -7.41% | -4.60 | 1394.71% | 0.00% | 0.00% | 2.46% | -6.46 | -9.22 | — | 36.28 |
| INBX | Inhibrx Biosciences, Inc. | $74.13 | 1.08B | +370% | -93% | +699% | — | 0.12 | 1.47 | 982.91 | 0.03 | — | 1.47 | -1042.50% | -165724.00% | 843786.00% | 1905.92% | 1880.87% | 690.69% | 0.06 | -24.57 | 3.94 | 3.76 | -0.08 | -237695.00% | -8889.00% | -45.00% | -100.22% | -4.77 | 1117.95% | 0.00% | 0.00% | 39.05% | -0.16 | -0.26 | 260.17 | -3.58 |
| NKTR | Nektar Therapeutics | $68.98 | 1.4B | -92% | -92% | — | — | -1.52 | 2.98 | 1.84 | -0.33 | — | 2.98 | 68.82% | -106.88% | -120.86% | -124.10% | 143.06% | -33.90% | 1.69 | -3.74 | 4.26 | 4.18 | -0.67 | -6017.00% | 922.00% | -842.00% | -97.90% | -2.86 | 241.42% | 0.00% | 0.00% | 15.02% | -0.27 | -0.16 | 0.29 | -16.15 |
| PGEN | Precigen, Inc. | $3.79 | 1.14B | +633% | -73% | — | +239% | -3.94 | 12.93 | 126.87 | -3.28 | -19.23 | 33.38 | -8.71% | -3440.23% | -3216.18% | -160.80% | -3010.47% | -85.20% | 0.14 | -22504.83 | 4.76 | 4.60 | 0.19 | 2051.00% | -3695.00% | 1211.00% | -15.41% | -3.17 | -1735.60% | 0.00% | 0.00% | 4.73% | -3.00 | -5.28 | 103.33 | -19.72 |
| RLAY | Relay Therapeutics, Inc. | $10.26 | 1.78B | +180% | -62% | — | — | -6.08 | 2.96 | 109.40 | -5.44 | — | 2.96 | 76.83% | -1971.59% | -1800.58% | -41.12% | -108.03% | -37.05% | 0.06 | — | 22.61 | 3.28 | 0.17 | -3178.00% | 5344.00% | -608.00% | -14.04% | -9.21 | -84.17% | 0.00% | 0.00% | 0.06% | -5.38 | -6.90 | 106.04 | 13.52 |
| SNDX | Syndax Pharmaceuticals, I… | $21.71 | 1.89B | +262% | +64,186% | — | — | -6.72 | 29.67 | 11.13 | -6.06 | — | 29.67 | 95.96% | -158.45% | -165.60% | -161.82% | 196.12% | -45.50% | 0.00 | -8.08 | 4.40 | 3.60 | 0.54 | -1153.00% | 62784.00% | 1756.00% | -16.85% | -2.69 | 232.09% | 0.00% | 0.00% | 17.03% | -5.58 | -4.71 | 8.84 | -1.10 |
| TERN | Terns Pharmaceuticals, In… | $42.12 | 3.79B | — | — | — | — | -3.12 | 0.80 | — | 0.79 | — | 0.80 | 0.00% | — | — | -29.56% | 1106.27% | -28.10% | 0.00 | — | 23.14 | 22.89 | 1.59 | -1181.00% | — | 388.00% | -25.25% | -4.47 | 760.80% | 0.00% | 0.00% | 29.11% | 0.78 | 1.13 | — | 7.82 |
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
- CEO
- Harpreet Singh
- Employees
- 554
- Beta
- 1.36
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.10 ÷ $10.79) − 1 = -52.73% (DCF, example).